Optimizing drug combinations for recurrent high grade astrocytic glioma using patient-derived organoids

Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma

This study is testing a new way to find the best drug combinations for treating recurrent high-grade brain tumors using samples from patients' tumors grown in the lab.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 21 Years to 99 Years
• Sex: All
• Sponsor: National University Hospital, Singapore (Academic / other)
• Drugs / interventions: Chemotherapy, immunotherapy
• Locations: 2 sites (Singapore and 1 other locations)
• Trial ID: NCT05532397 on ClinicalTrials.gov

What this trial studies

This interventional study focuses on evaluating the feasibility of the Quadratic Phenotypic Optimization Platform (QPOP) in treating recurrent high grade astrocytic glioma. Brain tumor samples will be collected from patients to generate patient-derived organoids (PDOs), which will then undergo drug screening to identify optimal drug combinations. The study aims to establish organoid models that reflect the biological characteristics of gliomas and assess their therapeutic responses to various drug combinations. Additionally, non-invasive imaging tools will be utilized to monitor treatment effects and correlate them with clinical outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 21 and older with suspected high grade astrocytic glioma who are fit for standard treatment involving surgery and adjuvant chemoradiotherapy.

Not a fit: Patients who are not candidates for surgery or those with a life expectancy of less than three months may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more effective personalized treatment options for patients with recurrent high grade astrocytic glioma.

How similar studies have performed: While the application of QPOP in this context is relatively novel, similar approaches using patient-derived organoids have shown promise in other studies.

Eligibility criteria

Inclusion Criteria:

Pre-screening:

1. Patients 21 years of age or older, with ECOG performance status 0 to 2, and with a life expectancy of more than 3 months with suspected high grade astrocytic glioma, fit for treatment comprising standard-of-care therapy with adjuvant temozolomide and radiotherapy if the diagnosis of high grade astrocytoma is pathologically confirmed.
2. Signed informed consent obtained before any study specific procedure. Subjects must be able to understand and be willing to sign the written informed consent.

   * Patients will be enrolled at the time of initial surgery but study imaging and further PDO generation will not take place if the patient is subsequently found not to meet the histological criteria or will not be receiving standard adjuvant temozolomide/ radiotherapy.

All subsequent criteria apply to the main study only:

1. Patients 21 years of age or older, with ECOG performance status 0 to 2, and life expectancy of more than 3 months with pathologically confirmed high grade astrocytic glioma, having undergone first-line standard-of-care therapy with surgery/biopsy followed by temozolomide and radiotherapy. Subjects with truncated adjuvant chemoradiotherapy may be enrolled at the Principal Investigator's discretion.
2. Documented tumor progression based on standard clinical, radiological or histological criteria, and deemed suitable for second line systemic therapy.
3. Sufficient tumor tissue available for PDO generation at baseline and at least one available or pending QPOP result.
4. Adequate organ function as defined by:

1\. Bone marrow function i. Haemoglobin ≥ 9g/dl ii. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L iii. Platelet count ≥ 100 x 109/L. 2. Liver function i. Bilirubin \< 2.5x upper limit of normal (ULN) ii. Alanine transaminase (ALT) and aspartate transaminase (AST) \< 2.5x ULN or \< 5x ULN if liver metastases are present iii. Prothrombin time (PT) within the normal range for the institution. 3. Renal function i. Plasma creatinine \<1.5x institutional ULN 5) Capable of swallowing tablets. 6) Recovery from any previous drug- or procedure-related toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 Grade 0 or 1 (except alopecia), or to baseline preceding the prior treatment.

Exclusion Criteria (both pre-screening/ main study)

1. Chemotherapy, radiotherapy, surgery, immunotherapy or other therapy within 2 weeks of study entry.
2. Pregnancy or breastfeeding at the point where systemic anti-cancer therapy is initiated. Women of childbearing potential must have a negative pregnancy test at the point where systemic anti-cancer therapy is initiated. Women of childbearing potential and men, must agree to use adequate contraception (barrier method of birth control) while on anti-cancer treatment and until at least 3 months after the last study drug administration.
3. Concurrent cancer which is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumours (Ta, Tis \& T1) or any cancer curatively treated less than 5 years prior to study entry.
4. Patients with leptomeningeal dissemination of disease and/or pure spinal high grade gliomas will be excluded.
5. Kidney disease which would clinically disqualify the subject from serial MRI scans with gadolinium contrast.

Where this trial is running

Singapore and 1 other locations

• Department of Hematology-Oncology, National University Hospital — Singapore, Singapore (Recruiting)
• Ng Teng Fong General Hospital — Singapore, Singapore (Not_yet_recruiting)

Study contacts

• Principal investigator: Andrea Wong — National University Hospital, Singapore
• Study coordinator: Andrea Wong

Conditions Glioma, Astrocytic; QPOP; patient-derived organoids; TMZ/RT resistance